<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dobutamine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dobutamine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Dobutamine: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11939" href="/d/html/11939.html" rel="external">see "Dobutamine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13243" href="/d/html/13243.html" rel="external">see "Dobutamine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F162001"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Adrenergic Agonist Agent;</li>
<li>
                        Inotrope</li></ul></div>
<div class="block doa drugH1Div" id="F161962"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="544fdb8d-9360-4b5b-be1d-3c8dd40a45be">Acute decompensated heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute decompensated heart failure:</b>
<b>Note:</b> May consider for short-term use in patients with low cardiac index and hypotension or end-organ hypoperfusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV: </b>Initial: 2 to 5 mcg/kg/minute; titrate based on clinical end point (eg, systemic perfusion or end-organ perfusion); usual dosage range: 2 to 10 mcg/kg/minute; maximum dose: 20 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-28923988','lexi-content-ref-Dunlay.1','lexi-content-ref-30175599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-28923988','lexi-content-ref-Dunlay.1','lexi-content-ref-30175599'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="69341349-2ce2-472f-af23-cc4f03c9b01e">Inotropic support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Inotropic support (off-label use): Note:</b> In patients with shock (eg, sepsis) who fail to meet hemodynamic goals with vasopressor therapy (eg, norepinephrine), dobutamine may be added to vasopressor therapy if there is continued hypoperfusion despite volume resuscitation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-23353941','lexi-content-ref-34605781']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-23353941','lexi-content-ref-34605781'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV: </b>Initial: 2 to 5 mcg/kg/minute; titrate based on clinical end point (eg, BP, end-organ perfusion); usual dosage range: 2 to 10 mcg/kg/minute; however, doses as low as 0.5 mcg/kg/min have been used in less severe cardiac decompensation; maximum dose: 20 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956225','lexi-content-ref-17720019','lexi-content-ref-Manaker.2021','lexi-content-ref-26597979','lexi-content-ref-23353941','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956225','lexi-content-ref-17720019','lexi-content-ref-Manaker.2021','lexi-content-ref-26597979','lexi-content-ref-23353941','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="816bf8c8-c754-4895-93c3-f12572e0aa7d">Stress echocardiography, routine</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress echocardiography, routine (diagnostic agent) (off-label use): Continuous infusion:</b>
<b>IV:</b> Initial: 5 mcg/kg/minute; increase at 3-minute intervals to 10 mcg/kg/minute, then 20 mcg/kg/minute, then 30 mcg/kg/minute, and then 40 mcg/kg/minute. May coadminister atropine in patients who do not achieve target heart rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31740370','lexi-content-ref-26961077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31740370','lexi-content-ref-26961077'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76d21cdb-9574-4966-ad02-6ff68bb271a5">Stress echocardiography, viability assessment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress echocardiography, viability assessment (diagnostic agent) (off-label use):</b>
<b>Continuous infusion:</b>
<b>IV:</b> Initial: 2.5 mcg/kg/minute; increase at 5-minute intervals in 2.5 mcg/kg/minute increments until contractile response is noted, up to a maximum dose of 10 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32833510','lexi-content-ref-31740370','lexi-content-ref-16569554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32833510','lexi-content-ref-31740370','lexi-content-ref-16569554'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990147"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> In patients with CrCl &lt;20 mL/minute receiving dobutamine continuous infusion for treatment of acute decompensated heart failure, dobutamine-induced myoclonus has been reported as a rare, but perhaps underrecognized, adverse effect (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17959575','lexi-content-ref-36686274','lexi-content-ref-15102987']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17959575','lexi-content-ref-36686274','lexi-content-ref-15102987'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (excreted in the urine as inactive metabolites) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14871156','lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14871156','lexi-content-ref-expert.doh'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Dialysis removal unknown (some expected based on small volume of distribution); no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.doh'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Dialysis removal unknown (some expected based on small volume of distribution); no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.doh'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.doh'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment likely to be necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-expert.doh']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-expert.doh'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987478"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doo drugH1Div" id="F56817385"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Class 1, 2, and 3 obesity (BMI ≥30 kg/m<sup>2</sup>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous infusion:</b>
<b>IV:</b> Use <b>ideal body weight</b> for initial weight-based dosing, then titrate to hemodynamic effect and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380','lexi-content-ref-expert.doo']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380','lexi-content-ref-expert.doo'])">Ref</a></span>). During therapy, clinicians should <b>not</b> change dosing weight from one weight metric to another (ie, actual body weight to/from ideal body weight) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380','lexi-content-ref-expert.doo']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380','lexi-content-ref-expert.doo'])">Ref</a></span>). Refer to "Dosing: Adult" for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For dobutamine stress test dosing, use <b>actual body weight</b> for all BMI categories (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21183730','lexi-content-ref-7808046','lexi-content-ref-expert.doo']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21183730','lexi-content-ref-7808046','lexi-content-ref-expert.doo'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">There is a paucity of studies evaluating the influence of obesity on dobutamine dosing or pharmacokinetics. One observational study of patients undergoing dobutamine stress testing using a weight-based protocol (and use of atropine) supports the protocolized use of actual body weight for all classes of obesity in this setting; however, this may not be applicable to the general population receiving dobutamine as a continuous infusion for inotropic support (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21183730','lexi-content-ref-7808046']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21183730','lexi-content-ref-7808046'])">Ref</a></span>). Dobutamine has a small volume of distribution with a short half-life enabling rapid titration to the desired effect. Due to the short onset of action and small volume of distribution, rapid titration to clinical effect after initial dosing is possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33622380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33622380'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F161963"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F161981"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13243" href="/d/html/13243.html" rel="external">see "Dobutamine: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aaecd9a-fa24-4a15-9c5b-a253afdc5ee0">Hemodynamic support</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodynamic support: </b>Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: Initial: 0.5 to 1 mcg/kg/minute; titrate gradually every few minutes until desired response achieved; usual range: 2 to 20 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-29538053','lexi-content-ref-20956230','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-29538053','lexi-content-ref-20956230','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51107932"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51107933"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F161929"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris (1% to 3%), chest pain (1% to 3%), increased heart rate (10%), increased systolic blood pressure (8%), palpitations (1% to 3%), premature ventricular contractions (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased blood pressure, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased serum potassium</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Localized phlebitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (Wirtz 1995), bradycardia (Olszowska 2012), cardiomyopathy (Chandraprakasam 2015), coronary artery vasospasm (Yamagishi 1998), heart block (Vaidyanathan 2008), left ventricular dysfunction (takotsubo syndrome) (Mangolini 2020), torsade de pointes (Quan 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia (Maaliki 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (Poldermans 1993), myoclonus (Noel 2022), shivering (Poldermans 1993)</p></div>
<div class="block coi drugH1Div" id="F161944"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to dobutamine or sulfites (some contain sodium metabisulfate), or any component of the formulation; hypertrophic cardiomyopathy with outflow tract obstruction (formerly known as idiopathic hypertrophic subaortic stenosis).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pheochromocytoma.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> When utilized for stress testing, additional contraindications according to the American Society of Nuclear Cardiology include patients with recent (&lt;2 to 4 days) myocardial infarction, unstable angina, severe aortic stenosis, atrial tachyarrhythmias with uncontrolled ventricular response, prior history of ventricular tachycardia, uncontrolled hypertension (&gt;200/110 mm Hg), and aortic dissection or large aortic aneurysm (ASNC [Henzlova 2016]).</p></div>
<div class="block war drugH1Div" id="F161926"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Arrhythmias: Ventricular arrhythmias, including nonsustained ventricular tachycardia and supraventricular arrhythmias, have been reported (Tisdale 1995). Observe closely for arrhythmias in patients with decompensated heart failure; sudden cardiac death has been observed (O’Connor 1999; Pickworth 1992; Young 2000). Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate.</p>
<p style="text-indent:-2em;margin-left:4em;">• BP effects: An increase in BP is more common due to augmented cardiac output, but hypotension secondarily to vasodilation may occur at higher doses.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure complications: An increased risk of hospitalization and death has been observed with prolonged use in New York Heart Association Class III/IV heart failure patients (O’Connor 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Tachycardia: May cause dose-related increases in heart rate.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ventricular ectopy: May exacerbate ventricular ectopy (dose related).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Ineffective therapeutically in the presence of mechanical obstruction such as severe aortic stenosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias (ACC/AHA/ESC [Zipes 2006]; Tisdale 1995).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypovolemia: If needed, correct hypovolemia first to optimize hemodynamics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Active myocardial ischemia/myocardial infarction (post): Use with caution in patients with active myocardial ischemia or recent myocardial infarction; can increase myocardial oxygen demand.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Monoamine oxidase inhibitors: Use with extreme caution in patients taking monoamine oxidase inhibitors; prolong hypertension may result from concurrent use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium sulfite: Product may contain sodium sulfite.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: Use with caution in older adults; start at lower end of the dosage range.</p></div>
<div class="block foc drugH1Div" id="F161937"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg/mL (250 mL); 2 mg/mL (250 mL); 4 mg/mL (250 mL); 250 mg/20 mL (20 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg/mL (20 mL)</p></div>
<div class="block geq drugH1Div" id="F161922"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323116"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DOBUTamine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">12.5 mg/mL (per mL): $0.39 - $0.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (DOBUTamine in D5W Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $0.07 - $0.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866642"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 12.5 mg/mL (20 mL)</p></div>
<div class="block adm drugH1Div" id="F161941"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Always administer via infusion device; administer into large vein.</p>
<p style="text-indent:-2em;margin-left:2em;">May be a vesicant; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Extravasation management:</b> If extravasation occurs, stop infusion immediately; leave cannula/needle in place temporarily but do <b>NOT</b> flush the line; gently aspirate extravasated solution, then remove needle/cannula; elevate extremity; apply dry, warm compresses; initiate phentolamine antidote in severe cases (eg, when local tissue concentration is high) in addition to supportive management (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913','lexi-content-ref-32341081','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913','lexi-content-ref-32341081','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Phentolamine:</i>
<b>SUBQ: </b>Dilute 5 to 10 mg in 10 mL NS and administer into extravasation site as soon as possible after extravasation; if IV catheter remains in place, administer initial dose intravenously through the infiltrated catheter; may repeat in 60 minutes if patient remains symptomatic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternatives to phentolamine:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Nitroglycerin topical 2% ointment: Apply a 1-inch strip to the site of ischemia to cover affected area; may repeat every 8 hours as necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913','lexi-content-ref-36938775'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Terbutaline: <b>SUBQ:</b> Infiltrate extravasation area with terbutaline 1 mg using a solution of terbutaline 1 mg diluted in 10 mL NS. May repeat dose after 15 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913','lexi-content-ref-36938775']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913','lexi-content-ref-36938775'])">Ref</a></span>).</p></div>
<div class="block admp drugH1Div" id="F52612601"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: Continuous IV infusion: Vials (concentrated solution) must be diluted prior to administration; premixed IV solutions (1,000 mcg/mL, 2,000 mcg/mL, 4,000 mcg/mL) are available. Administer as a continuous IV infusion via an infusion device. Central line administration is preferred; if central line not available, may administer for a short duration through a peripheral IV catheter placed in a large vein or via intraosseous access (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-20956230','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-20956230','lexi-content-ref-manu.1'])">Ref</a></span>). Administration into an umbilical arterial catheter is <b>not</b> recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Domonoske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Domonoske.1'])">Ref</a></span>). Frequent monitoring of the IV catheter site is recommended to rapidly identify extravasation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24420913']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24420913'])">Ref</a></span>). Refer to institutional policies and procedures; catheter placement/size and vasopressor concentration may vary depending on institution.</p>
<p style="text-indent:-2em;margin-left:2em;">Rate of infusion (mL/hour) = dose (mcg/kg/minute) × weight (kg) × 60 minutes/hour divided by the concentration (mcg/mL)</p></div>
<div class="block uica drugH1Div" id="F14471789"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 250 mg in 500 mL (concentration: 500 <b>mcg</b>/mL), 500 mg in 250 mL (concentration: 2,000 <b>mcg</b>/mL), <b>or</b> 1,000 mg in 250 mL (concentration: 4000 <b>mcg</b>/mL) of D5W or NS</p></div>
<div class="block uicp drugH1Div" id="F14471790"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 1,000 <b>mcg</b>/mL, 2,000 <b>mcg</b>/mL, <b>or</b> 4,000 <b>mcg</b>/mL</p></div>
<div class="block use drugH1Div" id="F161940"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Acute decompensated heart failure:</b> Short-term management of patients with cardiac decompensation.</p></div>
<div class="block off-label drugH1Div" id="F25725334"><span class="drugH1">Use: Off-Label: Adult</span><p>Inotropic support; Stress echocardiography (diagnostic agent)</p></div>
<div class="block mst drugH1Div" id="F162009"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">DOBUTamine may be confused with DOPamine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299223"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of COMT</p></div>
<div class="block dri drugH1Div" id="F161931"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May diminish the therapeutic effect of DOBUTamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of DOBUTamine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COMT Inhibitors: May increase the serum concentration of COMT Substrates.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F13314045"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Dobutamine should not be used as a diagnostic agent for stress testing during pregnancy; use should be avoided when other options are available (ESC [Regitz-Zagrosek 2018]). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant female. Appropriate medications should not be withheld due to concerns of fetal teratogenicity. Dobutamine use during the post-resuscitation phase may be considered; however, the effects of inotropic support on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support (ACLS) guidelines (AHA [Jeejeebhoy 2015 ]).</p></div>
<div class="block brc drugH1Div" id="F20305984"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if dobutamine is present in breast milk.</p></div>
<div class="block mop drugH1Div" id="F161935"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP, heart rate, ECG, hemodynamic parameters as appropriate (eg, CVP, RAP, MAP, CI, PCWP, SVR, ScvO<sub>2</sub> or SvO<sub>2</sub>); intravascular volume status; kidney function; urine output.</p>
<p style="text-indent:0em;margin-top:2em;">Consult individual institutional policies and procedures.</p></div>
<div class="block pha drugH1Div" id="F161925"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Dobutamine, a racemic mixture, stimulates myocardial beta<sub>1</sub>-adrenergic receptors primarily by the (+) enantiomer and some alpha<sub>1</sub> receptor agonism by the (-) enantiomer, resulting in increased contractility and heart rate, and stimulates both beta<sub>2</sub>- and alpha<sub>1</sub>-receptors in the vasculature. Although beta<sub>2</sub> and alpha<sub>1</sub> adrenergic receptors are also activated, the effects of beta<sub>2</sub> receptor activation may equally offset or be slightly greater than the effects of alpha<sub>1</sub> stimulation, resulting in some vasodilation in addition to the inotropic and chronotropic actions (Leier 1988; Majerus 1989; Ruffolo 1987). Lowers central venous pressure and wedge pressure, but has little effect on pulmonary vascular resistance (Leier 1977; Leier 1978). </p></div>
<div class="block phk drugH1Div" id="F161943"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: 1 to 10 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 10 to 20 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: In tissues and hepatically (via conjugation and methylation) to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (as inactive metabolites).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F161947"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine hameln | Dobutrex</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Dobucard | Dobutamina | Dobutamina bioquim | Dobutamina drawer | Dobutamina fabra | Dobutamina gray | Dobutamina Norgreen | Dobutrex | E.m.c. dobutamina</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutamin hameln | Inotop</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutamine bc | Dobutamine claris | Dobutamine HCL | Dobutrex</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Dobumin | Dobutamine abbott | Dobutin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine Baxter | Dobutamine eg | Dobutamine mayne pharma (ben) | Dobutrex</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutamin hameln | Dobutrex</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de dobutamina | Dobtan | Dobu | Dobutal | Dobutamol | Dobutanil | Dobutariston | Dobutrex | Hibutan</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutamin fresenius | Dobutrex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutrex | Feng hai fen</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Autobod | Dobutamina | Dobutrex | Docarip | Dotropina | Duvig</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamin | Dobutamin admeda | Dobutamin hameln</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutamin carinopharm | Dobutamin hameln | Dobutamin hexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Dobutrex | Dotropina | Inoject</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Dobutamina | Dobutamina sanderson</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dobcard | Dobuject | Dobutamine claris | Dobutamine hameln | Dobutamine HCL | Dobutamine merck | Dobutamine mylan | Dobuthaver | Dobutrex | Mekard</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutrex | Dubuject</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Dobucor | Dobutamina abbott | Dobutamina inibsa | Dobutamina rovi | Dobutrex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamin abbott | Dobutrex</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine Aguettant | Dobutamine Baxter | Dobutamine dakota | Dobutamine merck | Dobutamine Panpharma | Dobutamine Qualimed | Dobutamine winthrop | Dobutrex</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutrex | Posiject</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine HCL | Dobutan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamin admeda | Dobutamin hameln | Dobutamina panpharma | Dobutrex</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cardiject | Dobuca | Dobuject | Doburan | Dobutamin | Dobutamine | Dobutel | Dobutrex | Domine | Dominic | Inodex | Inotrop</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Posiject</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cardiforce | Dobicard | Dobier s | Dobunex pf | Dobusol | Dobustat | Inoject</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dobutamina abbott | Dobutamina bioindustria | Dobutamina Hikma | Dobutrex | Miozac</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Bubucin | Doburack | Dobutamine | Dobutrex | Dobux | Dobux nichiiko | Dopmin | Doputamin | Doputamin Fuji | Doputamin h hexal | Hercarenone d | Retamex</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aukomine | Dobamine | Dobuject | Doburan | Dobutamine | Dobutamine hcl and dextrose | Dobutamine hcl injection huons | Dobutrex | Myungmoon Dobutamine HCL | Toburex</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutrex</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutrex</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamin | Dobutamina panpharma | Dobutamine claris | Dobutamine hameln | Dobutrex</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamin | Dobutamine claris | Dobutamine mylan | Dobutrex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Dobutrex</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adregotec | Corbusin | Cryobutol | Dobuject | Dobutamina | Dobutamina gi tecn</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Mobitil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutamine CF | Dobutamine claris</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutrex</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutamine claris | Dobutamine hameln</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dobutamina | Dobutrex</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abbott dobutamine hydrochloride | Cardease | Cardiotrex | Cardob | Dobine | Dobucard | Dobucore | Dobuject | Dobulex | Dobumarc | Dobumean | Doburan | Dobutamine | Dobutamine Baxter | Dobutrex | Dobutrim | Dobuzef | Inocard | Pusogard</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Dobamin | Dobutine | Dobutrex</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutrex</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine HCL | Dobutrex</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Dasomin | Dobucor | Dobutamina | Dobutamina Aps | Dobutamina Claris | Dobutamina Generis | Dobutamina genthon | Dobutamina Hikma | Dobutina | Inotrex</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamina sanderson | E.m.c.</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Dobcard | Dobuject | Dobutasel | Dobuthaver</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin admeda | Dobutamina | Dobutamina panpharma</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin admeda | Dobutamine | Dobutel | Dobutrex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Dobuject | Dobutamin | Dobutamine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin hameln | Dobutrex</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine | Dobutrex</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin hameln | Inotop</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dobutamin | Dobutrex</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Cardiject | Dobucin | Dobutamine | Dobutamine abbott | Dobutamine hcl DBL | Dobutel | Dobutrex</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine mylan | Dobutamine Panpharma</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Dobcard | Dobutamin | Dobutasel | Dobuthaver | Mekard</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Butamine | Dobuha | Dobuject | Dobutamine | Dobutamine HCL | Dobutrex | Easydobu | Gendobu | Utamine</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cardiject | Clebutam | Dobutamin admeda | Dobutamin ebewe | Dobutel</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dobutam | Dobutamina | Dobutamina blaufarma | Dobutamina fu | Duvig</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Doburan | Dobutamina | Dobutrex | Dobuxin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Dobutamine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed April 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17720019">
<a name="17720019"></a>Annane D, Vignon P, Renault A, et al; CATS Study Group. Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. <i>Lancet</i>. 2007;370(9588):676-684. doi:10.1016/S0140-6736(07)61344-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/17720019/pubmed" id="17720019" target="_blank">17720019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10400006">
<a name="10400006"></a>Bax JJ, Poldermans D, Elhendy A, et al. Improvement of Left Ventricular Ejection Fraction, Heart Failure Symptoms and Prognosis After Revascularization in Patients With Chronic Coronary Artery Disease and Viable Myocardium Detected by Dobutamine Stress Echocardiography. <i>J Am Coll Cardiol</i>. 1999;34(1):163-169.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/10400006/pubmed" id="10400006" target="_blank">10400006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15542956">
<a name="15542956"></a>Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. <i>Crit Care Med</i>. 2004;32(11)(suppl):S455-S465. doi:10.1097/01.ccm.0000142909.86238.b1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/15542956/pubmed" id="15542956" target="_blank">15542956</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17959575">
<a name="17959575"></a>Boord A, Benson B. Myoclonus associated with continuous dobutamine infusion in a patient with end-stage renal disease. <i>Am J Health Syst Pharm</i>. 2007;64(21):2241-2243. doi:10.2146/ajhp060326<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/17959575/pubmed" id="17959575" target="_blank">17959575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29538053">
<a name="29538053"></a>Cavigelli-Brunner A, Hug MI, Dave H, et al. Prevention of low cardiac output syndrome after pediatric cardiac surgery: a double-blind randomized clinical pilot study comparing dobutamine and milrinone. <i>Pediatr Crit Care Med</i>. 2018;19(7):619-625. doi:10.1097/PCC.0000000000001533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/29538053/pubmed" id="29538053" target="_blank">29538053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26425489">
<a name="26425489"></a>Chandraprakasam S, Kanuri S, Hunter C. Mid-ventricular variant of dobutamine-induced stress cardiomyopathy. <i>Res Cardiovasc Med</i>. 2015;4(2):e25223. doi:10.5812/cardiovascmed.4(2)2015.25223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/26425489/pubmed" id="26425489" target="_blank">26425489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23353941">
<a name="23353941"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637. doi:10.1097/CCM.0b013e31827e83af<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/23353941/pubmed" id="23353941" target="_blank">23353941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31010560">
<a name="31010560"></a>Dempsey E, Rabe H. The use of cardiotonic drugs in neonates. <i>Clin Perinatol</i>. 2019;46(2):273-290. doi:10.1016/j.clp.2019.02.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/31010560/pubmed" id="31010560" target="_blank">31010560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.1">
<a name="Hospira.1"></a>Dobutamine in 5% dextrose injection [prescribing information]. Lake Forest, IL: Hospira Inc; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hospira.2">
<a name="Hospira.2"></a>Dobutamine injection [prescribing information]. Lake Forest, IL: Hospira Inc; November 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Dobutamine injection [product monograph]. Mississauga, Ontario, Canada: Hikma Canada Limited; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Domonoske.1">
<a name="Domonoske.1"></a>Domonoske C. Appendix A: Common neonatal intensive care unit (NICU) medication guidelines. In: Eichenwald EC, Hansen AR, Martin CR, Stark AR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 8th ed. Lippincott Williams &amp; Wilkins; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dunlay.1">
<a name="Dunlay.1"></a>Dunlay SM, Colucci WS. Management of refractory heart failure with reduced ejection fraction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33622380">
<a name="33622380"></a>Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. <i>Crit Care</i>. 2021;25(1):77. doi:10.1186/s13054-021-03495-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/33622380/pubmed" id="33622380" target="_blank">33622380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.doo">
<a name="expert.doo"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-expert.doh">
<a name="expert.doh"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10440157">
<a name="10440157"></a>Fragasso G, Lu C, Dabrowski P, Pagnotta P, Sheiban I, Chierchia SL. Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. <i>J Am Coll Cardiol</i>. 1999;34(2):441-447. doi:10.1016/s0735-1097(99)00231-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/10440157/pubmed" id="10440157" target="_blank">10440157</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32833510">
<a name="32833510"></a>Garcia MJ, Kwong RY, Scherrer-Crosbie M, et al; American Heart Association Council on Cardiovascular Radiology and Intervention and Council on Clinical Cardiology. State of the art: imaging for myocardial viability: a scientific statement from the American Heart Association. <i>Circ Cardiovasc Imaging</i>. 2020;13(7):e000053. doi:10.1161/HCI.0000000000000053<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/32833510/pubmed" id="32833510" target="_blank">32833510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17174798">
<a name="17174798"></a>Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS; Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. <i>J Nucl Cardiol</i>. 2006;13(6):e80-e90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/17174798/pubmed" id="17174798" target="_blank">17174798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26961077">
<a name="26961077"></a>Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. Erratum to: ASNC imaging guidelines for SPECT nuclear cardiology procedures: stress, protocols, and tracers. <i>J Nucl Cardiol</i>. 2016;23(3):640-642. doi:10.1007/s12350-016-0463-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/26961077/pubmed" id="26961077" target="_blank">26961077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26443610">
<a name="26443610"></a>Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/26443610/pubmed" id="26443610" target="_blank">26443610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29707527">
<a name="29707527"></a>Joynt C, Cheung PY. Treating hypotension in preterm neonates with vasoactive medications. <i>Front Pediatr</i>. 2018;6:86. doi:10.3389/fped.2018.00086<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/29707527/pubmed" id="29707527" target="_blank">29707527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21183730">
<a name="21183730"></a>Kittipovanonth M, Bernheim AM, Scott CG, Barnes ME, Shub C, Pellikka PA. Is the standard weight-based dosing of dobutamine for stress testing appropriate for patients of widely varying body mass index? <i>J Cardiovasc Pharmacol Ther</i>. 2011;16(2):173-177. doi:10.1177/1074248410384709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/21183730/pubmed" id="21183730" target="_blank">21183730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation</i>. 2010;122(18)(suppl 3):S876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14871156">
<a name="14871156"></a>Lehtonen LA, Antila S, Pentikäinen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. <i>Clin Pharmacokinet</i>. 2004;43(3):187-203. doi:10.2165/00003088-200443030-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/14871156/pubmed" id="14871156" target="_blank">14871156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2901217">
<a name="2901217"></a>Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. <i>Am J Cardiol</i>. 1988;62(8):86E-93E.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/2901217/pubmed" id="2901217" target="_blank">2901217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-679437">
<a name="679437"></a>Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. <i>Circulation</i>. 1978;58(3 Pt 1):466-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/679437/pubmed" id="679437" target="_blank">679437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-884803">
<a name="884803"></a>Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. <i>Circulation</i>. 1977;56(3):468-472.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/884803/pubmed" id="884803" target="_blank">884803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30175599">
<a name="30175599"></a>Lewis TC, Aberle C, Altshuler D, Piper GL, Papadopoulos J. Comparative effectiveness and safety between milrinone or dobutamine as initial inotrope therapy in cardiogenic shock. <i>J Cardiovasc Pharmacol Ther</i>. 2019;24(2):130-138. doi:10.1177/1074248418797357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/30175599/pubmed" id="30175599" target="_blank">30175599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16569554">
<a name="16569554"></a>Ling LH, Christian TF, Mulvagh SL, et al. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. <i>Am Heart J</i>. 2006;151(4):882-889. doi:10.1016/j.ahj.2005.06.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/16569554/pubmed" id="16569554" target="_blank">16569554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33564531">
<a name="33564531"></a>Maaliki N, Ali AA, Izzo C, Patel H, Antoine S. Alarming eosinophilia from dobutamine infusion. <i>Cureus</i>. 2021;13(1):e12530. doi:10.7759/cureus.12530<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/33564531/pubmed" id="33564531" target="_blank">33564531</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2671957">
<a name="2671957"></a>Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR Jr. Dobutamine: ten years later. <i>Pharmacotherapy</i>. 1989;9(4):245-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/2671957/pubmed" id="2671957" target="_blank">2671957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manaker.2021">
<a name="Manaker.2021"></a>Manaker S. Use of vasopressors and inotropes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32696875">
<a name="32696875"></a>Mangolini VI, Baron GB, Amaro G, et al. Dobutamine-induced Takotsubo syndrome during stress echocardiogram - an unusual but potentially severe association. <i>Rev Assoc Med Bras (1992)</i>. 2020;66(6):724-727. doi:10.1590/1806-9282.66.6.724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/32696875/pubmed" id="32696875" target="_blank">32696875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1585858">
<a name="1585858"></a>Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiography in detecting coronary artery disease. <i>Am J Cardiol</i>. 1992;69(16):1269-1273. doi:10.1016/0002-9149(92)91219-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/1585858/pubmed" id="1585858" target="_blank">1585858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26597979">
<a name="26597979"></a>Mouncey PR, Osborn TM, Power GS, et al. Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. <i>Health Technol Assess</i>. 2015;19(97):i-xxv,1-150. doi:10.3310/hta19970<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/26597979/pubmed" id="26597979" target="_blank">26597979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36686274">
<a name="36686274"></a>Noel E, Fayoda B, Rabbani R, Benjamin YS, Lee J, Gillespie A. Dobutamine-induced myoclonus in a peritoneal dialysis patient: case report. <i>Kidney Med</i>. 2022;5(3):100591. doi:10.1016/j.xkme.2022.100591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/36686274/pubmed" id="36686274" target="_blank">36686274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10385768">
<a name="10385768"></a>O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). <i>Am Heart J</i>. 1999;138(1, pt 1):78-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/10385768/pubmed" id="10385768" target="_blank">10385768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22298172">
<a name="22298172"></a>Olszowska M, Musiałek P, Drwiła R, Podolec P. Progressive bradycardia with increasing doses of dobutamine leading to stress echo interruption. <i>Cardiol J</i>. 2012;19(1):79-80. doi:10.5603/cj.2012.0012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/22298172/pubmed" id="22298172" target="_blank">22298172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9884380">
<a name="9884380"></a>Patel MB, Kaplan IV, Patni RN, et al. Sustained Improvement in Flow-Mediated Vasodilation After Short-Term Administration of Dobutamine in Patients With Severe Congestive Heart Failure. <i>Circulation</i>. 1999;99(1):60-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/9884380/pubmed" id="9884380" target="_blank">9884380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2231992">
<a name="2231992"></a>Paulman PM, Cantral K, Meade JG, et al. Dobutamine Overdose. <i>JAMA</i>. 1990;264(18):2386-2387.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/2231992/pubmed" id="2231992" target="_blank">2231992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25272316">
<a name="25272316"></a>Peake SL, Delaney A, Bailey M, et al; ARISE Investigators; ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. <i>N Engl J Med</i>. 2014;371(16):1496-1506. doi:10.1056/NEJMoa1404380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/25272316/pubmed" id="25272316" target="_blank">25272316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956225">
<a name="20956225"></a>Peberdy MA, Callaway CW, Neumar RW, et al; American Heart Association. Part 9: post-cardiac arrest care: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation</i>. 2010;122(18)(suppl 3):S768-S786. doi:10.1161/CIRCULATIONAHA.110.971002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/20956225/pubmed" id="20956225" target="_blank">20956225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7808046">
<a name="7808046"></a>Pellikka PA, Roger VL, Oh JK, Miller FA, Seward JB, Tajik AJ. Stress echocardiography. Part II. Dobutamine stress echocardiography: techniques, implementation, clinical applications, and correlations. <i>Mayo Clin Proc</i>. 1995;70(1):16-27. doi:10.1016/S0025-6196(11)64660-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/7808046/pubmed" id="7808046" target="_blank">7808046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31740370">
<a name="31740370"></a>Pellikka PA, Arruda-Olson A, Chaudhry FA, et al. Guidelines for performance, interpretation, and application of stress echocardiography in ischemic heart disease: from the American Society of Echocardiography. <i>J Am Soc Echocardiogr</i>. 2020;33(1):1-41.e8. doi:10.1016/j.echo.2019.07.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/31740370/pubmed" id="31740370" target="_blank">31740370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22058104">
<a name="22058104"></a>Phillips MS. Standardizing I.V. Infusion Concentrations: National Survey Results. <i>Am J Health Syst Pharm</i>. 2011;68(22):2176-2182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/22058104/pubmed" id="22058104" target="_blank">22058104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1617912">
<a name="1617912"></a>Pickworth KK. Long-term dobutamine therapy for refractory congestive heart failure. <i>Clin Pharm</i>. 1992;11(7):618-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/1617912/pubmed" id="1617912" target="_blank">1617912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8491005">
<a name="8491005"></a>Poldermans D, Fioretti PM, Forster T, et al. Dobutamine stress echocardiography for assessment of perioperative cardiac risk in patients undergoing major vascular surgery. <i>Circulation</i>. 1993;87(5):1506-1512. doi:10.1161/01.cir.87.5.1506<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/8491005/pubmed" id="8491005" target="_blank">8491005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2022044">
<a name="2022044"></a>Previtali M, Lanzarini L, Ferrario M, Tortorici M, Mussini A, Montemartini C. Dobutamine versus dipyridamole echocardiography in coronary artery disease. <i>Circulation</i>. 1991;83(5)(suppl):III27-III31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/2022044/pubmed" id="2022044" target="_blank">2022044</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19353679">
<a name="19353679"></a>Quan F, Peng G, Kangan C, Dayi H, Cuilan L, Richard CC. Dobutamine infusion for unmasking long QT syndrome and torsades de pointes. <i>Clin Cardiol</i>. 2009;32(6):E79-E82. doi:10.1002/clc.20248<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/19353679/pubmed" id="19353679" target="_blank">19353679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24420913">
<a name="24420913"></a>Reynolds PM, Maclaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. <i>Pharmacotherapy</i>. 2014;34(6):617-632. doi:10.1002/phar.1396<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/24420913/pubmed" id="24420913" target="_blank">24420913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7884117">
<a name="7884117"></a>Rich MN, Woods WL, Davila-Roman VG, et al. A Randomized Comparison of Intravenous Amrinone Versus Dobutamine in Older Patients With Decompensated Congestive Heart Failure. <i>J Am Geriatr Soc</i>. 1995;43(3):271-274.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/7884117/pubmed" id="7884117" target="_blank">7884117</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11794169">
<a name="11794169"></a>Rivers E, Nguyen B, Havstad S, et al. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock. <i>N Engl J Med</i>. 2001;345(19):1368-1377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/11794169/pubmed" id="11794169" target="_blank">11794169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3310640">
<a name="3310640"></a>Ruffolo RR Jr. The pharmacology of dobutamine. <i>Am J Med Sci</i>.1987;294(4):244-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/3310640/pubmed" id="3310640" target="_blank">3310640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32341081">
<a name="32341081"></a>Smolders EJ, Benoist GE, Smit CCH, Ter Horst P. An update on extravasation: basic knowledge for clinical pharmacists. <i>Eur J Hosp Pharm</i>. 2020;28(3):165–167. doi:10.1136/ejhpharm-2019-002152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/32341081/pubmed" id="32341081" target="_blank">32341081</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36938775">
<a name="36938775"></a>Stefanos SS, Kiser TH, MacLaren R, Mueller SW, Reynolds PM. Management of noncytotoxic extravasation injuries: a focused update on medications, treatment strategies, and peripheral administration of vasopressors and hypertonic saline. <i>Pharmacotherapy.</i> 2023;43(4):321-337. doi:10.1002/phar.2794<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/36938775/pubmed" id="36938775" target="_blank">36938775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7568905">
<a name="7568905"></a>Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. <i>Prog Cardiovasc Dis</i>. 1995;38(2):167-180.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/7568905/pubmed" id="7568905" target="_blank">7568905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18791534">
<a name="18791534"></a>Vaidyanathan L, Anand N, Stead LG, Boie ET, Sztajnkrycer MD, Goyal DG. Dobutamine-induced complete heart block. <i>South Med J</i>. 2008;101(10):1038-1042. doi:10.1097/SMJ.0b013e31817e55d9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/18791534/pubmed" id="18791534" target="_blank">18791534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28923988">
<a name="28923988"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/28923988/pubmed" id="28923988" target="_blank">28923988</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15102987">
<a name="15102987"></a>Wierre L, Decaudin B, Barsumau J, et al. Dobutamine-induced myoclonia in severe renal failure. <i>Nephrol Dial Transplant</i>. 2004;19(5):1336-1337. doi:10.1093/ndt/gfh132<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/15102987/pubmed" id="15102987" target="_blank">15102987</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7725721">
<a name="7725721"></a>Wirtz CE. Sustained atrial fibrillation after dobutamine stress echocardiography in an older patient with left atrial enlargement. <i>West J Med</i>. 1995;162(3):268-269.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/7725721/pubmed" id="7725721" target="_blank">7725721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9559438">
<a name="9559438"></a>Yamagishi H, Watanabe H, Toda I, et al. A case of dobutamine-induced coronary arterial spasm with ST-segment elevation. <i>Jpn Circ J</i>. 1998;62(2):150-151. doi:10.1253/jcj.62.150<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/9559438/pubmed" id="9559438" target="_blank">9559438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24635773">
<a name="24635773"></a>Yealy DM, Kellum JA, Huang DT, et al; ProCESS Investigators. A randomized trial of protocol-based care for early septic shock.<i> N Engl J Med</i>. 2014;370(18):1683-1693. doi:10.1056/NEJMoa1401602<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/24635773/pubmed" id="24635773" target="_blank">24635773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11016488">
<a name="11016488"></a>Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. <i>J Heart Lung Transplant</i>. 2000;19(8)(suppl):S49-S57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/11016488/pubmed" id="11016488" target="_blank">11016488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16935995">
<a name="16935995"></a>Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. <i>Circulation</i>. 2006;114(10):e385-e484.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/dobutamine-drug-information/abstract-text/16935995/pubmed" id="16935995" target="_blank">16935995</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9380 Version 278.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
